Explore a selection of our essential drug information below, or:
Identification
- Generic Name
- Veru-111
- DrugBank Accession Number
- DB16462
- Background
VERU-111, an investigational drug intended for various therapeutic uses, was under investigation in clinical trials NCT04842747, NCT03752099, NCT04388826, NCT04844749, NCT05008510, and NCT05079360. These trials aimed to evaluate its efficacy, safety, and tolerability in conditions such as SARS-CoV-2 infection, metastatic castration-resistant prostate cancer (mCRPC), respiratory distress syndrome in adults, and metastatic triple-negative breast cancer.
- Type
- Small Molecule
- Groups
- Investigational
- Structure
Structure for Veru-111 (DB16462)
- Weight
- Average: 377.4
Monoisotopic: 377.137556104 - Chemical Formula
- C21H19N3O4
- Synonyms
- [2-(1H-indol-3-yl)-1H-imidazol-4-yl](3,4,5-trimethoxyphenyl)methanone
- Methanone, [2-(1H-indol-3-yl)-1H-imidazol-5-yl](3,4,5-trimethoxyphenyl)-
- External IDs
- ABI-231
- APP-111
- VERU 111
- Veru-111
- VERU111
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
Veru-111 is a selective tubulin inhibitor currently being tested for the treatment of pancreatic cancer. Veru-111 represses alpha- and beta-tublin subunits through enhanced expression of miR-200C. In both melanoma and prostate cancer cell lines, it has displayed strong antiproliferative activity. It also prevents microtubule polymerization and causes cell cycle arrest in the G2/M phase, which suggests anti-tumor properties.
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Categories
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 37L1JX37J5
- CAS number
- 1332881-26-1
- InChI Key
- WQGVHOVEXMOLOK-UHFFFAOYSA-N
- InChI
- InChI=1S/C21H19N3O4/c1-26-17-8-12(9-18(27-2)20(17)28-3)19(25)16-11-23-21(24-16)14-10-22-15-7-5-4-6-13(14)15/h4-11,22H,1-3H3,(H,23,24)
- IUPAC Name
- 3-[4-(3,4,5-trimethoxybenzoyl)-1H-imidazol-2-yl]-1H-indole
- SMILES
- COC1=CC(=CC(OC)=C1OC)C(=O)C1=CNC(=N1)C1=CNC2=C1C=CC=C2
References
- General References
- Kashyap VK, Wang Q, Setua S, Nagesh PKB, Chauhan N, Kumari S, Chowdhury P, Miller DD, Yallapu MM, Li W, Jaggi M, Hafeez BB, Chauhan SC: Therapeutic efficacy of a novel betaIII/betaIV-tubulin inhibitor (VERU-111) in pancreatic cancer. J Exp Clin Cancer Res. 2019 Jan 23;38(1):29. doi: 10.1186/s13046-018-1009-7. [Article]
- External Link [Link]
- Information [Link]
- External Links
- ChemSpider
- 28642581
- ChEMBL
- CHEMBL2163631
- ZINC
- ZINC000095555435
- PDBe Ligand
- KUM
- PDB Entries
- 6o61
Clinical Trials
- Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package Phase Status Purpose Conditions Count Start Date Why Stopped 100+ additional columns Unlock 175K+ rows when you subscribe.View sample data3 Completed Treatment Coronavirus Disease 2019 (COVID‑19) / Seasonal Allergic Rhinitis 1 somestatus stop reason just information to hide 3 Terminated Treatment Androgen Resistant Prostatic Cancer / Metastatic Castration-Resistant Prostate Cancer (mCRPC) 1 somestatus stop reason just information to hide 2 Completed Treatment Acute Respiratory Distress Syndrome (ARDS) / Coronavirus Disease 2019 (COVID‑19) 1 somestatus stop reason just information to hide 2 Withdrawn Treatment Metastatic Breast Cancer 1 somestatus stop reason just information to hide 2 Withdrawn Treatment Metastatic Triple Negative Breast Cancers 1 somestatus stop reason just information to hide
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source logP 3.35 Chemaxon pKa (Strongest Acidic) 9.9 Chemaxon pKa (Strongest Basic) 3.92 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 5 Chemaxon Hydrogen Donor Count 2 Chemaxon Polar Surface Area 89.23 Å2 Chemaxon Rotatable Bond Count 6 Chemaxon Refractivity 114.79 m3·mol-1 Chemaxon Polarizability 39.93 Å3 Chemaxon Number of Rings 4 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule Yes Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
- Chromatographic Properties
Collision Cross Sections (CCS)
Not Available
Drug created at January 21, 2021 01:43 / Updated at July 17, 2024 10:37